Scinai Biopharma Services has named Eilon Elmalem as Site Head of its recently acquired Yavne CDMO facility, with the role commencing June 14, 2026. In this capacity, he will assume full responsibility for site operations, engineering activities and ongoing integration efforts following the Recipharm acquisition.

Elmalem brings over two decades of experience in biopharmaceutical engineering, process development and industrial infrastructure management. His previous senior leadership roles at Merck and Sigma-Aldrich Millipore involved overseeing R&D, manufacturing and major capital investment programs across Israel, Europe and the United States.

The transition under current site head Dr. Sylvia Kachalsky began May 10 and aims to ensure continuity ahead of her retirement later in 2026. This leadership change is designed to bolster Scinai’s CDMO operational excellence and support the planned expansion of the Yavne facility.